Research Paper Volume 16, Issue 6 pp 5050—5064

Omilancor mitigates the senescence of nucleus pulposus cells induced by DDP through targeting MAP2K6

class="figure-viewer-img"

Figure 2. MAP2K6 was upregulated in DDP-induced cellular senescence model. (A, B) Rat NP cells were exposed to DDP (mM, 24h), IL-1β (100ng/ml, 24h), and TNF-α (50ng/ml) to establish an in vitro senescence NP cell model, which was confirmed by SA-β-gal staining and the corresponding quantitative analysis. (Original magnification 200×, scale bar = 200 μm; Red arrow: positive cells). (C) RT-qPCR results depict the expression levels of MAP2K6 following different treatments. (D, E) Immunocytochemistry (ICC) staining and the accompanying quantitative analysis of MAP2K6 in control (CTR) or DDP-treated Rat NP cell models. (Original magnification 400×, scale bar = 100 μm). (F) Western Blot analysis illustrating the expression of MAP2K6 in control (CTR) or DDP-treated Rat NP cell models. (G, H) Immunofluorescence (IF) staining of IVDs tissue in rat model and quantitative assessment of MAP2K6 expression in control (CTR) or IDD rats after 8 weeks of operation. (original magnification 400×, scale bar = 100 μm). CTR, control group; DDP, cisplatin treatment. n = 3 each group. Data are represented as mean ± standard deviation. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001, as determined by t-test.